Catalog No.: PC-20004Not For Human Use, Lab Use Only.
TG2-179-1 is a potent, selective and covalently inhibitor of deubiquitinase (DUB) BRCA1-associated protein-1 (BAP1), covalently binds to the active site of BAP1 (Cys91), exhibits potent cytotoxic activity against colon cancer cells.
TG2-179-1 is a potent, selective and covalently inhibitor of deubiquitinase (DUB) BRCA1-associated protein-1 (BAP1), covalently binds to the active site of BAP1 (Cys91), exhibits potent cytotoxic activity against colon cancer cells.
TG2-179-1 has potent cytotoxic activity against colon cancer cells with IC50 of <10 uM against HCT116, HT29 and SW48 cells, and BAP1-proficient cells are more sensitive to TG2-179-1 than BAP1-deficient cells.
TG2-179-1 exerts its cytotoxic activity against colon cancer cells as well as other types of cancer cells, such as mesothelioma and ccRCC, by targeting BAP1.
TG2-179-1 induces replication defects in colon cancer cells and increases the level of γ-H2AX in a dose-dependent manner in HCT116 cells, which is similar to BAP1 depletion.
TG2-179-1 inhibits the growth of colon tumors in mice.
